Shopping Cart
Remove All
Your shopping cart is currently empty
Actoxumab (Synonyms: Anti-C. difficile Toxin A Recombinant Antibody)
Catalog No. T77473 Copy Product Info
Purity: 95%
🥰Excellent
Actoxumab is a humanized monoclonal antibody targeting Clostridium difficile toxin A (TcdA), preventing the binding of TcdA to target cells and neutralizing toxin activity by inhibiting the first step of TcdA.
Actoxumab
Copy Product Info🥰Excellent
Catalog No. T77473
Synonyms Anti-C. difficile Toxin A Recombinant Antibody
Actoxumab is a humanized monoclonal antibody targeting Clostridium difficile toxin A (TcdA), preventing the binding of TcdA to target cells and neutralizing toxin activity by inhibiting the first step of TcdA.
Actoxumab
Cas No. 1245634-25-6
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $332 | In Stock | In Stock | |
| 5 mg | $996 | In Stock | In Stock | |
| 10 mg | $1,577 | - | In Stock | |
| 25 mg | $2,680 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.52% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Actoxumab is a humanized monoclonal antibody targeting Clostridium difficile toxin A (TcdA), preventing the binding of TcdA to target cells and neutralizing toxin activity by inhibiting the first step of TcdA. |
| In vitro | Actoxumab (10 mg/kg) significantly inhibited cell rounding activity in Vero cells when treated with 2 ng/mL TcdA. [1] |
| In vivo | Actoxumab-bezlotoxumab (0.1, 1 or 10 mg/kg) significantly protected mice in a dose-dependent manner from Clostridium difficile toxin attack models. In acute and severe CDI models, Actoxumab-bezlotoxumab prevents inflammation and damage associated with TcdA and TcdB. [1] |
| Synonyms | Anti-C. difficile Toxin A Recombinant Antibody |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | Cdiff Toxin A |
| Molecular Weight | 145 kDa |
| Cas No. | 1245634-25-6 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Actoxumab | purchase Actoxumab | Actoxumab cost | order Actoxumab | Actoxumab in vivo | Actoxumab in vitro | Actoxumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.